FDA approves long-acting injection formulation of aripiprazole

Source: PharmaTimes Area: News According to PharmaTimes approval has been granted in the United States for a long-acting, once monthly intramuscular injection formulation of aripiprazole (Abilify® Maintena®) for the treatment of schizophrenia. Approval was based on data from a 52-week Phase III maintenance trial of the drug in patients with schizophrenia, which showed that it significantly delayed time to relapse compared to placebo, and lowered the percentage of subjects experiencing relapse, the groups note. No further trial data are provided in the PharmaTimes story.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news